Nykode Therapeutics AS (VACBF)
OTCMKTS
· Delayed Price · Currency is USD
0.2749
0.00 (0.00%)
At close: Apr 23, 2025
Nykode Therapeutics AS Employees
Nykode Therapeutics AS had 139 employees as of December 31, 2024. The number of employees decreased by 34 or -19.65% compared to the previous year.
Employees
139
Change (1Y)
-34
Growth (1Y)
-19.65%
Revenue / Employee
$67,338
Profits / Employee
-$285,449
Market Cap
86.71M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
Elite Pharmaceuticals | 64 |
CytoDyn | 9 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Nykode Therapeutics AS News
- 6 months ago - Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe - GlobeNewsWire
- 9 months ago - Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines - GlobeNewsWire
- 11 months ago - Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting - GlobeNewsWire
- 11 months ago - Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy - GlobeNewsWire
- 1 year ago - Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer - GlobeNewsWire
- 1 year ago - Nykode Therapeutics - Quarterly report Q1 2024 - GlobeNewsWire
- 1 year ago - Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer - GlobeNewsWire
- 1 year ago - Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer - GlobeNewsWire